Lanomycin (Amikacin Sulfate)

Lanomycin, an aminoglycoside antibiotic, is employed for serious infections caused by gram‑negative organisms.

• Severe gram‑negative infections: Provides rapid bactericidal activity against susceptible strains.
• Sepsis: Contributes to systemic infection control when combined with appropriate therapy.
• Hospital‑acquired pneumonia: Targets resistant pathogens in lower respiratory tract infections.
• Urinary tract infections: Eradicates complicated UTIs caused by resistant gram‑negative bacteria.
• Intra‑abdominal infections: Assists in managing polymicrobial abdominal sepsis.

• Amikacin sulfate binds to the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. This action leads to a bactericidal effect against susceptible gram‑negative organisms, disrupting essential cellular functions and resulting in cell death.

Amikacin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects

• Nephrotoxicity: Elevated serum creatinine and reduced renal clearance.
• Ototoxicity: Tinnitus or hearing loss, especially with prolonged use.
• Vestibular dysfunction: Dizziness or balance disturbances.
• Rash or mild skin eruption.
• Fever without clear source.

Serious or Rare Side Effects

• Anaphylactic reaction: Rapid onset of airway compromise and hypotension.
• Severe allergic dermatitis: Extensive skin involvement requiring medical intervention.
• Respiratory distress: Bronchospasm or pulmonary edema.
• Irreversible hearing loss: Permanent auditory damage.
• Acute renal failure: Sudden loss of kidney function.
• Neuromuscular blockade: Muscle weakness leading to respiratory failure.

Before initiating Lanomycin, clinicians should assess patient‑specific risk factors and monitor for toxicity.

• Renal function monitoring: Check serum creatinine and urine output before and during therapy.
• Auditory assessment: Perform baseline and periodic hearing tests, especially in prolonged courses.
• Dose adjustment in renal impairment: Reduce dose or extend interval based on glomerular filtration rate.
• Avoid concurrent nephrotoxic agents: Limit use with vancomycin, loop diuretics, or contrast media.
• Pregnancy caution: Category D; weigh maternal benefits against fetal risks.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Amikacin can interact with several drug classes, altering efficacy or increasing toxicity.

Major Interactions (Avoid)

• Concurrent nephrotoxic antibiotics (e.g., vancomycin, gentamicin): Heightened risk of renal injury.
• Ototoxic agents (e.g., furosemide, cisplatin): Amplified hearing loss.
• Neuromuscular blocking drugs (e.g., succinylcholine): Potentiated muscle weakness.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: May exacerbate renal dysfunction.
• NSAIDs: Can reduce renal clearance of amikacin.
• Loop diuretics: Increase risk of ototoxicity when used together.
• Antacids containing magnesium or aluminum: May affect absorption of other co‑administered oral drugs.